Clinical Study Results
1. Study Name
Title of the study: A Randomized, Open-label, Phase 3 Study in Subjects
With Relapsed and Refractory Multiple Myeloma
Receiving Carfilzomib in Combination With
Dexamethasone, Comparing Once-weekly Versus
Twice-weekly Carfilzomib Dosing
Brief Title: Once-weekly Versus Twice-weekly Carfilzomib in
Combination With Dexamethasone in Adults With Relapsed
and Refractory Multiple Myeloma (A.R.R.O.W.)
Protocol Number: 20140355
EU Trial Number: 2014-005325-12
Other Identifiers: NCT02412878
Date of This 17 December 2020
Summary:
What does this summary cover?
This summary shows the main results from one clinical study, the A.R.R.O.W. study.
The results are only for this study. Other studies may find different results.
Researchers and health authorities look at the results of many studies to decide
which medicines work best and are safest for patients.
Amgen has committed to make research results available to the public. This
summary has been provided as part of that commitment and should not be used for
any other purpose. It should not be considered to make a claim for any product or to
guide treatment decisions.
1